Abstract
Due to the time-dependent loss of cytochrome P450 (P450)-mediated metabolism in freshly isolated hepatocytes, several types of culture systems have been developed to extend their lifespan. The aim of this study was to evaluate the ability of monolayer cultures of rat hepatocytes to determine the in vitro CLint compared with suspensions of freshly isolated hepatocytes. Seven compounds were incubated in rat hepatocyte suspensions and monolayer cultures, and in vitro CLint was obtained via metabolite formation (12 pathways) or substrate depletion approaches. Only two compounds (tolbutamide and 7-ethoxycoumarin) gave comparable (within 2-fold) in vitro CLint in both suspensions and monolayer cultures. Although the overall rank order of compounds was the same in both models (covering a range of 3-4 orders of magnitude), the prediction of in vitro CLint for high-turnover compounds (seven pathways) was lower for monolayer cultures compared with suspensions, probably due to an uptake rate limitation leading to increases in KM. In general, there was an average 50% loss of the P450 activity in monolayers based on a decrease in Vmax relative to suspensions. However, monolayer cultures gave a higher estimation of in vitro CLint for the low-turnover compound S-warfarin compared with fresh cell suspensions due to a decrease in the KM of the four individual metabolites. The use of hepatocyte monolayer cultures may offer the potential advantage of extending the lower end of the usable clearance range (below 0.1 μl/min/106 cells) for predicting in vivo CLint
Footnotes
-
↵1 Current address: Servier Research and Development, Fulmer Hall, Slough, UK.
-
Financial support for this project was provided by Celltech Research and Development. Part of this study was presented at the 6th International ISSX Meeting, Oct 7-11, 2001, Munich, Germany, and appeared in abstract form in Drug Metab Rev , . (Suppl 1):..
-
ABBREVIATIONS: P450, cytochrome P450; TOL, tolbutamide; WAR, 8-hydroxywarfarin; PHE, phenytoin; 7-EC, 7-ethoxycoumarin; DZ, diazepam; DEX, dextromethorphan; PROP, propranolol; HTOL, hydroxytolbutamide; MEM, methoxymorphinan; DOR, dextrorphan; FCS, fetal calf serum; HMM, hepatocyte maintenance media; NDZ, nordiazepam.
- Received March 25, 2004.
- Accepted October 1, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|